Relmada Therapeutics Inc

NASDAQ RLMD

Data sourced from

and

Daily

Download Data

Relmada Therapeutics Inc Enterprise Value (EV) on June 03, 2024

Relmada Therapeutics Inc Enterprise Value (EV) is NA on June 03, 2024, a NA change year over year. Enterprise Value is a measure of a company's total value, including both its equity and debt. It represents the theoretical takeover price of a company and is often used in valuation methods. Enterprise value is calculated as the sum of a company's market capitalization, total debt, and subtracting its cash and short-term investments.

Relmada Therapeutics Inc 52-week high Enterprise Value (EV) is NA on June 03, 2024, which is NA below the current Enterprise Value (EV).
Relmada Therapeutics Inc 52-week low Enterprise Value (EV) is NA on June 03, 2024, which is NA below the current Enterprise Value (EV).
Relmada Therapeutics Inc average Enterprise Value (EV) for the last 52 weeks is NA.

NASDAQ: RLMD

Relmada Therapeutics Inc

CEO	Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD
IPO Date	Oct. 9, 2014
Location	United States
Headquarters	2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134
Employees	20
Sector	Healthcare
Industry	Biotechnology

Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Key trends